Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | EIF2AK4 | Q9P2K8 | 10/20 | 0.40 |
| ▸ | JAK2 | O60674 | 6/20 | 0.40 |
| ▸ | JAK3 | P52333 | 6/20 | 0.40 |
| ▸ | JAK1 | P23458 | 5/20 | 0.40 |
| ▸ | NRAS | P01111 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | BLK | P51451 | 1/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.37 |
| ▸ | CCNH | P51946 | 1/20 | 0.37 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995794 | 1.00 | FLT3 (0.44) | FLT3EIF2AK4JAK2JAK3JAK1 | |
| SCHEMBL2054144 | 0.88 | ADORA2A (0.39) | EIF2AK4JAK2JAK3JAK1 | |
| SCHEMBL1997366 | 0.88 | ADORA2A (0.39) | EIF2AK4JAK2JAK3JAK1 | |
| SCHEMBL1992453 | 0.87 | IRAK4 (0.51) | FLT3EIF2AK4JAK2JAK3JAK1 | |
| SCHEMBL1992451 | 0.87 | IRAK4 (0.51) | FLT3EIF2AK4JAK2JAK3JAK1 | |
| SCHEMBL2001368 | 0.85 | JAK2 (0.38) | FLT3EIF2AK4JAK2JAK3JAK1 | |
| SCHEMBL2000440 | 0.85 | IRAK4 (0.54) | FLT3NRASIRAK4 | |
| SCHEMBL2038354 | 0.79 | EIF2AK4 (0.48) | EIF2AK4JAK2JAK3JAK1 | |
| SCHEMBL1992661 | 0.77 | IRAK4 (0.58) | FLT3NRASIRAK4LCKRET | |
| SCHEMBL1992660 | 0.77 | IRAK4 (0.58) | FLT3NRASIRAK4LCKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | FLT3 21/4885EIF2AK4 211/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.